# TYK Medicines

Source: https://onco.cc/companies/tyk-medicines/  
OnCo record `tyk-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TYK Medicines is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the EGFR inhibitor asandeutertinib (TY-9591) and TYK-00540 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and brain and spinal cord tumours.

## Summary

TYK Medicines (Zhejiang Tongyuankang) is a Chinese biotechnology company listed in Hong Kong that discovers, develops and manufactures small-molecule targeted cancer drugs, with research centres in Changxing and Zhengzhou. Its EGFR inhibitor asandeutertinib (TY-9591) has been approved in China for EGFR-mutant lung cancer with brain metastases. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (1 in phase 3 or 2/3): FLETEO (phase 3, Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Ce...), NCT06950086 (phase 1/2, Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors) and NCT05948813 (phase 2, TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Zhejiang Tongyuankang Pharmaceutical; 同源康医药
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.tykmedicines.com
- Ticker: HKEX:2410

## Sources

- Official website: https://www.tykmedicines.com
- ClinicalTrials.gov: trials led by TYK Medicines: https://clinicaltrials.gov/search?lead=TYK%20Medicines%2C%20Inc

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [TY-9591](https://onco.cc/drugs/ty-9591/)
- trials: [Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)](https://onco.cc/trials/fleteo/), [Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06950086/), [TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases](https://onco.cc/trials/nct05948813/)

---
JSON: https://onco.cc/api/v1/entities/tyk-medicines.json